- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06542874
Une étude de recherche comparant dans quelle mesure différentes doses du médicament NNC0487-0111 réduisent la glycémie chez les personnes atteintes de diabète de type 2
Innocuité et efficacité du NNC0487-0111 sous-cutané une fois par semaine et une fois par jour par voie orale chez les participants atteints de diabète de type 2 - une étude de recherche de dose
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Elsterwerda, Allemagne, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda, Allemagne, 04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen, Allemagne, 45136
- InnoDiab Forschung GmbH
-
Hamburg, Allemagne, 22607
- Wendisch/Dahl Hamburg
-
Hamburg, Allemagne, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, Allemagne, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Allemagne, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Kyustendil, Bulgarie, 2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil, Bulgarie, 2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv, Bulgarie, 4002
- DCC Sveti Georgi EOOD
-
Plovdiv, Bulgarie, 4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv, Bulgarie, 4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv, Bulgarie, 4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia, Bulgarie, 1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia, Bulgarie, 1431
- UMHAT "Aleksandrovska"
-
Sofia, Bulgarie, 1000
- Medical centre Regina Life Clinic EOOD
-
Sofia, Bulgarie, 1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia, Bulgarie, 1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna, Bulgarie, 9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
-
Karlovac, Croatie, 47000
- Opca bolnica Karlovac
-
Krapinske Toplice, Croatie, 49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice, Croatie, 49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek, Croatie, 31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek, Croatie, 31 000
- Klinicki bolnicki centar Osijek
-
Varaždin, Croatie, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin, Croatie, 42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Croatie, 10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, Croatie, 51 000
- KBC Rijeka, Endokrinologija
-
Rijeka, Primorje-Gorski Kotar County, Croatie, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
A Coruña, Espagne, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, Espagne, 08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta, Espagne, 41950
- Hospital Vithas Sevilla
-
Madrid, Espagne, 28007
- Hospital Gregorio Marañón
-
Pontevedra, Espagne
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander, Espagne, 39008
- Hospital Universitario Marqués de Valdecilla
-
Seville, Espagne, 41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville, Espagne, 41010
- Hospital Infanta Luisa
-
Seville, Espagne, 41950
- Hospital Nisa Sevilla Aljarafe
-
Seville, Espagne, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
-
Athens, Grèce, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, Grèce, 12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens, Grèce, 11527
- "Laiko" General Hospital of Athens
-
Thessaloniki, Grèce, GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grèce, GR-57001
- "Thermi" Private Hosital
-
Thessaloniki, Grèce, 564 29
- 424 Military General Training Hospital
-
Thessaloniki, Grèce, 57001
- "Thermi" Private Hosital
-
Thessaloniki, Grèce, 54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grèce, 564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Budapest, Hongrie, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, Hongrie, 1134
- MH Egészségügyi Központ
-
Debrecen, Hongrie, 4031
- Debreceni Egyetem
-
Debrecen, Hongrie, H-4031
- Debreceni Egyetem
-
Debrecen, Hongrie, H-4032
- Debreceni Egyetem
-
Gyula, Hongrie, 5700
- Békés Megyei Központi Kórház
-
Kaposvár, Hongrie, 7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár, Hongrie, H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hongrie, 4032
- Debreceni Egyetem
-
-
-
-
-
Aichi, Japon, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba, Japon, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba, Japon, 261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba, Japon, 260-0804
- Akaicho Clinic
-
Ibaraki, Japon, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japon, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo, Japon, 103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo, Japon, 104-0031
- Fukuwa Clinic
-
Tokyo, Japon, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japon, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japon, 880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki, Miyazaki, Japon, 880-0034
- Heiwadai Hospital
-
-
-
-
-
Bialystok, Pologne, 15-375
- Specderm Poznańska Spółka Jawna
-
Lublin, Pologne, 20-718
- EKAMED sp. z o.o.
-
Ruda Śląska, Pologne, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw, Pologne, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska, Gornoslaskie, Pologne, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Pologne, 31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim, Lesser Poland Voivodeship, Pologne, 32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica, Lower Silesian Voivodeship, Pologne, 59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica, Lower Silesian Voivodeship, Pologne, 59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Pologne, 20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Pologne, 08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Pologne, 15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok, Podlaskie Voivodeship, Pologne, 15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Pologne, 90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Brasov, Roumanie, 500101
- Mariodiab Clinic SRL
-
Timișoara, Roumanie, 300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara, Roumanie, 300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea, Bihor County, Roumanie, 410025
- SC Grand Med SRL
-
Oradea, Bihor County, Roumanie, 410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest, Bucharest, Roumanie, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest, Bucurestii, Roumanie, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, Roumanie, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş, Mureș County, Roumanie, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, Roumanie, 100018
- Novus Medical Clinica SRL
-
-
-
-
-
Poprad, Slovaquie, 05801
- DENTAVIA s.r.o.
-
Prešov, Slovaquie, 080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota, Slovaquie, 979 01
- OLIVER - MED s.r.o.
-
Žilina, Slovaquie, 010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy, Slovak Republic, Slovaquie, 93601
- Peter Farkas MD, s.r.o.
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles, California, États-Unis, 90057
- Velocity Clin Research LA
-
Santa Ana, California, États-Unis, 92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury, Connecticut, États-Unis, 06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island, Florida, États-Unis, 32003
- Fleming Island Ctr for Clin Res
-
Hollywood, Florida, États-Unis, 33024
- Encore Medical Research LLC
-
Miramar, Florida, États-Unis, 33027
- South Broward Research LLC
-
Orlando, Florida, États-Unis, 32825
- Florida Inst For Clin Res
-
Orlando, Florida, États-Unis, 32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka, Kansas, États-Unis, 66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah, Kentucky, États-Unis, 42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville, Maryland, États-Unis, 20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill, Maryland, États-Unis, 20745
- MD Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Brigham & Women's Hospital
-
Methuen, Massachusetts, États-Unis, 01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy, Michigan, États-Unis, 48098
- Arcturus Healthcare, PLC
-
Troy, Michigan, États-Unis, 48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield, Missouri, États-Unis, 63005
- Clinical Research Professionals
-
City of Saint Peters, Missouri, États-Unis, 63303
- StudyMetrix Research LLC
-
-
New York
-
Albany, New York, États-Unis, 12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City, North Carolina, États-Unis, 28557
- Centricity Rsrch MHCity Multi
-
Statesville, North Carolina, États-Unis, 28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58104
- Lillestol Research LLC
-
Fargo, North Dakota, États-Unis, 58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman, Oklahoma, États-Unis, 73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh, Pennsylvania, États-Unis, 15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, États-Unis, 57702
- Health Concepts
-
-
Tennessee
-
Kingsport, Tennessee, États-Unis, 37660
- Holston Medical Group
-
Nashville, Tennessee, États-Unis, 37203
- Clinical Research Associates
-
Nashville, Tennessee, États-Unis, 37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas, Texas, États-Unis, 75230
- Velocity Clinical Res-Dallas
-
Houston, Texas, États-Unis, 77024
- Victorium Clinical Research
-
Houston, Texas, États-Unis, 77079
- PlanIt Research, PLLC
-
Houston, Texas, États-Unis, 77061
- Synergy Groups Medical
-
Lampasas, Texas, États-Unis, 76550
- Radiance Clinical Research
-
McKinney, Texas, États-Unis, 75069
- Tekton Research
-
Waco, Texas, États-Unis, 76708
- Hillcrest Family Health Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
Expérimental: NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Expérimental: NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Expérimental: NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Expérimental: NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Expérimental: NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Expérimental: NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Comparateur placebo: Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
Expérimental: NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Expérimental: NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Expérimental: NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in HbA1c
Délai: From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Relative change in body weight
Délai: From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Délai: From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Délai: From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Délai: From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
Délai: From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
Délai: From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Délai: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
Délai: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Délai: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Délai: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Délai: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Délai: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Délai: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Délai: From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
Délai: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
Délai: At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
Délai: From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publications et liens utiles
Publications générales
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NN9490-7678
- U1111-1296-9708 (Autre identifiant: World Health Organization (WHO))
- 2023-509412-28 (Autre identifiant: European Medical Agency (EMA))
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .